BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24867687)

  • 1. Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor.
    Nishio H; Yaguchi T; Sugiyama J; Sumimoto H; Umezawa K; Iwata T; Susumu N; Fujii T; Kawamura N; Kobayashi A; Park J; Aoki D; Kawakami Y
    Br J Cancer; 2014 Jun; 110(12):2965-74. PubMed ID: 24867687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
    Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
    Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
    J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.
    Watanabe M; Yamashita K; Kamachi H; Kuraya D; Koshizuka Y; Shibasaki S; Asahi Y; Ono H; Emoto S; Ogura M; Yoshida T; Ozaki M; Umezawa K; Matsushita M; Todo S
    Transplantation; 2013 Sep; 96(5):454-62. PubMed ID: 23860082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Zhu Q; Wu X; Wu Y; Wang X
    Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
    Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer.
    Kozakai N; Kikuchi E; Hasegawa M; Suzuki E; Ide H; Miyajima A; Horiguchi Y; Nakashima J; Umezawa K; Shigematsu N; Oya M
    Br J Cancer; 2012 Aug; 107(4):652-7. PubMed ID: 22805327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
    Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
    Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
    Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.
    Fukushima T; Kawaguchi M; Yorita K; Tanaka H; Takeshima H; Umezawa K; Kataoka H
    Neuro Oncol; 2012 Jan; 14(1):19-28. PubMed ID: 21968049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
    Sato M; Nakanishi K; Haga S; Fujiyoshi M; Baba M; Mino K; ; Niwa H; Yokoo H; Umezawa K; Ohmiya Y; Kamiyama T; Todo S; Taketomi A; Ozaki M
    Oncol Res; 2013; 21(6):333-43. PubMed ID: 25198663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts.
    Inokawa S; Watanabe T; Keino H; Sato Y; Hirakata A; Okada AA; Fukuda K; Fukushima A; Umezawa K
    Graefes Arch Clin Exp Ophthalmol; 2015 Apr; 253(4):557-63. PubMed ID: 25519802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102.
    Ohsugi T; Kumasaka T; Ishida A; Ishida T; Horie R; Watanabe T; Umezawa K; Yamaguchi K
    Leuk Res; 2006 Jan; 30(1):90-7. PubMed ID: 16002138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
    Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
    J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro.
    Liu H; Zhang G; Huang J; Ma S; Mi K; Cheng J; Zhu Y; Zha X; Huang W
    J Transl Med; 2016 Apr; 14(1):104. PubMed ID: 27118139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
    Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells.
    Noma N; Asagiri M; Takeiri M; Ohmae S; Takemoto K; Iwaisako K; Minato N; Maeda-Yamamoto M; Simizu S; Umezawa K
    Int Arch Allergy Immunol; 2015; 166(2):84-90. PubMed ID: 25791818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Shinoda K; Nakagawa K; Kosaka T; Tanaka N; Maeda T; Kono H; Mizuno R; Kikuchi E; Miyajima A; Umezawa K; Oya M
    Hum Immunol; 2010 Aug; 71(8):763-70. PubMed ID: 20573582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.